A Non-Traumatic Binder for Temporary Abdominal Wall Closure

NCT ID: NCT03815370

Last Updated: 2022-03-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-01

Study Completion Date

2023-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

At the end of most abdominal operations, the fascial layer is closed by stitching edges of the wound together. However, because of logistic and/or technical reasons or the patient's critical condition, the surgeon is forced to leave the abdomen open.

The current approach for temporary coverage of abdomen is vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site. Although this is the most successful and commonly used procedure, there are some limitations to this method. For example, VAT have little effect on preventing lateral movement of the wound edges. Therefore, VAT it is not the ideal procedure in aiding surgeons to closed the abdomen.

The purpose of this study is to compare usual care (vacuum or non-vacuum methods for temporary coverage of the OA) versus usual care plus a novel new abdominal binder device called ABRO™ that may aid in the closure of patients who undergo open abdomen closure procedures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At the end of most abdominal operations the fascial layer is closed primarily. However, because of logistic, physiological and or anatomical reasons, the surgeon needs to leave the abdomen open. In those circumstances, attempts to close the abdomen could potentially lead to unnecessary damage to the abdominal wall fascia, intra-abdominal hypertension, abdominal compartment syndrome and abdominal wall dehiscence post-operatively.

The use of the "open abdomen" (OA) in the post-operative period is not uncommon. Currently, three important trends provide grounds for increased use of this surgical strategy:

* Lifesaving surgical procedures in severely injured trauma patients.
* Surgical procedures performed in patients with non-traumatic surgical emergencies
* Abdominal catastrophes in elderly patients with pre-existing medical conditions. The OA is not a new strategy in the surgeon's armamentarium. A recent publication retrieved more than 1300 articles over the last 25 years relative to the management of the OA, published in the English language.5 However, the precise incidence of the OA is unknown. Nonetheless, hospitals around the world, particularly those that receive trauma victims, have an OA rate of 1-5% among their most critically ill surgical patients.

This lifesaving surgical strategy does not come without a price. The mortality rate of an OA is approximately 30%. There is also a wide range of complications linked to this procedure. The OA exposes large surface area of the body to the environment increasing fluid losses. Maintenance of adequate fluid and nutritional status of the patient are challenging in this setting.

Furthermore, the exposed abdominal cavity also poses greater risk for local contamination from external sources that could ultimately result in sepsis. Impaired abdominal wall function interferes with ventilatory mechanics. Consequently, patients with OA are prone to respiratory complications. However, the most dreaded complication of an OA is the formation of an enteroatmospheric fistula (EF). The incidence of EF is approximately 11-15%, and increases with time. Patients who have an OA for more than 8 days have an incidence of ECF as high as 25%, caused mainly by damage to the exposed bowel. Management this complication is extremely challenging, very costly, and carries a mortality rate of 36-64%.

In consideration of the foregoing considerations, early closure of the OA is undoubtedly the most effective way to prevent complications linked to this lifesaving surgical strategy. One of the most important barriers to early closure of the OA is lateral retraction of the fascial wound edges. Retraction presents as early as three days post-operatively, involves all layers of the abdominal wall and ultimately results in loss of domain. Moreover, generalized edema, atrophy and contraction of the abdominal muscles also contribute to a progressively larger defect in the fascia.Another important problem is "buckling" of the rectus abdominal muscles resulting in a "diamond" shape defect in the fascial that is very difficult to close.

Management of the OA prior to definitive closure call for temporary closure techniques. The three main objectives of temporary closure techniques are to prevent injury to the bowel, manage fluid loss from the abdominal cavity, and ultimately to facilitate primary closure. Early closure is dependent on technical factors and patients' underlying clinical condition. Despite all efforts to facilitate primary fascial closure, this condition is successfully achieved only in approximately 60% of the cases.

Currently, vacuum assisted techniques (VAT) are the most frequent, and arguably the most efficacious method for temporary coverage of the OA. Furthermore, VAT are particularly useful in the management of edema fluid, gastrointestinal and peritoneal secretions. Despite these important benefits, VAT provide minimal support to prevent lateral retraction of the abdominal wall fascial edges. Indeed, vacuum closure devices are not able to brace the abdominal wall and prevent lateralization of the rectus muscles even with maximum negative pressure. Moreover, excessive negative pressure applied to the abdominal cavity could potentially provoke severe injury to the intra-abdominal organs and interfere with physiologic functions.

Devices applied surgically to the abdominal wall are more effective in preventing lateral retraction of the fascial edges. However, these devices are stitched through the skin, subcutaneous tissue, muscle, and fascial layers. These stitches frequently cut through the aforementioned tissues because of the high pressure at the suture sites produced by counteracting forces. The resulting wounds encompass all layers of the abdominal wall including the fascia. Another important drawback of devices that require a surgical procedure for application is the need for frequent trips to operating room for assessment and potential adjustments. Furthermore, technical limitations inherit to surgically applied temporary closure devices result in undesirable delay for the initial placement. A recent report showed that the mean time from the primary operation to placement of the temporary closure device was 9.5 days.16 This is dangerously close to the critical period of EF formation and loss of abdominal domain.

Interim analysis of the data obtained from the initial randomized clinical trial to investigate the original prototype of the non-traumatic binder for abdominal wall closure (ABROTM) described in this protocol showed promising results (n=20 patients). The utilization of the original prototype of the ABROTM device resulted in 80% primary fascial closure rate compared to only 50% when VAT alone was employed. All patients (n=10) subjected to the application of the original prototype of the ABROTM device had their abdomen closed by primary fascial suture, without component separation or mesh. The ABROTM prototype resulted in greater than 65% reduction in the maximum width and the area of the fascial defects at 4 ± 1 days post-operative, whereas VAT alone resulted in a 5% increase. Moreover, interim analysis of the data showed that there were no complications from the use of the prototype of the ABROTM device. Therefore, it is anticipated that the use of the new ABROTM device in the proposed multicentre randomized controlled trial may have several advantages compared to preexisting methods for closure of the OA

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Trauma Abdominal Injury Abdominal Infection Abdominal Sepsis Abdominal Abscess Abdominal Aneurysm Abdominal Compartment Syndrome Peritonitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The purpose of this study is to compare usual care (vacuum or non-vacuum methods for temporary coverage of the OA) versus usual care plus the new abdominal binder device called ABRO™.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

It is impossible for the participant or anyone within the patients circle of care to be blinded in this study, as it is clear if the abdominal binder is on the participant or not. There is no way to blind in this interventional study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual Care

The current approach for temporary coverage of abdomen is called "vacuum assisted techniques (VAT)". This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site.

Group Type PLACEBO_COMPARATOR

Placebo Comparator: Usual Care

Intervention Type DEVICE

The current approach for temporary coverage of abdomen is called "vacuum assisted techniques (VAT)". This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site.

Device: ABRO™Binder Arm

Intervention is the usual care (listed above) plus a novel new abdominal binder device called ABRO™

Group Type EXPERIMENTAL

Experimental: ABRO™ Binder Arm

Intervention Type DEVICE

ABRO™ is an abdominal device designed to be positioned superficially on the abdominal skin of patients managed with the Open Abdomen strategy. The device is comprised of two rigid plates to stabilize the abdominal muscles thus preventing buckling of these. Another element of this novel device is the circumferential dynamic retainer (CDR). This one is passed behind the patient's back to provide more stability to the muscles in the abdomen keeping them in position to prevent lateral movement of them.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental: ABRO™ Binder Arm

ABRO™ is an abdominal device designed to be positioned superficially on the abdominal skin of patients managed with the Open Abdomen strategy. The device is comprised of two rigid plates to stabilize the abdominal muscles thus preventing buckling of these. Another element of this novel device is the circumferential dynamic retainer (CDR). This one is passed behind the patient's back to provide more stability to the muscles in the abdomen keeping them in position to prevent lateral movement of them.

Intervention Type DEVICE

Placebo Comparator: Usual Care

The current approach for temporary coverage of abdomen is called "vacuum assisted techniques (VAT)". This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mechanically ventilated patients, managed with the OA strategy.
* 16 years of age or older

Exclusion Criteria

* Patients who are pregnant
* Loss of any portion of the abdominal wall that could preclude primary closure
* Burn patients
* BMI greater than 40 kg/m2
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Unity Health Toronto

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joao Rezende-Neto, MD

Role: PRINCIPAL_INVESTIGATOR

Unity Health Toronto

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Columbian Hospital

New Westminster, British Columbia, Canada

Site Status NOT_YET_RECRUITING

Vancouver General Hospital

Vancouver, British Columbia, Canada

Site Status NOT_YET_RECRUITING

QEII Health Sciences Center

Halifax, Nova Scotia, Canada

Site Status NOT_YET_RECRUITING

St. Michael's Hospital

Toronto, Ontario, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Joao Rezende, MD

Role: CONTACT

416-864-5284

Sandy Trpcic

Role: CONTACT

416-864-6060 ext. 7131

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Vesna Ivkov

Role: primary

Vahid Mehrnoush

Role: primary

Lisa Julien

Role: primary

Sandy Trpcic

Role: primary

416-864-6060 ext. 7131

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17-249

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Abdominal aBscess Catheter Sclerotherapy (ABCS)
NCT06906029 NOT_YET_RECRUITING PHASE1/PHASE2
Abdominal Binder and Steps Trial
NCT04414384 COMPLETED NA